Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,425.65
(
1.42%
)
Dow Jones
49,310.32
(
0.00%
)
Brent Oil
99.74
(
-1.45%
)
Bitcoin
78,293.30
(
0.02%
)
News Focus
News Focus
Post# of 257442
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

masterlongevity

Send PM Follow Ignore
Followers 24
Posts 2597
Boards Moderated 0
Alias Born 01/07/2004

masterlongevity

Re: None

Wednesday, 05/19/2010 3:10:16 PM

Wednesday, May 19, 2010 3:10:16 PM

Post# of 257442
The 2nd Eli Lilly Gamma Secratase (LY450139) Ph 3 trial for Mild to moderate AD completed recruitment last week and results are expected in March 2012.

this drug has officially passed bapineuzumab in its ph 3 timeline and will be the next potential disease modifying AD therapy to report ph 3 results.


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today